After undergoing treatment for Stage 2 Hodgkins lymphoma, Hardee Bhavsar is on a journey to cross items off her bucket list ...

BeOne Medicines said the Food and Drug Administration has granted Breakthrough Therapy Designation for sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's ...

The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...

Still, for many people with stage 4 cancer, the goal shifts from cure to control. Doctors focus on slowing cancer growth, ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Medical oncologist Heather Parsons, MD, MPH, witnessed how cancer affects the entire family when her younger sister was ...

Every year, more than 80,000 Americans hear the life-changing words: You have Non-Hodgkin’s Lymphoma. That may not sound like a lot — until you realize it’s the entire population of ...